3.170SEK+5.32%Mkt Cap: 31.99M $P/E: 3.37Today
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of drug candidates to treat cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by…
Industry Peers
Biotechnology$130.23BUSDP/E 32.1
$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$61.34BUSDP/E 39.8
$45.95BUSDP/E 19.6
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.26BUSDP/E 26.6
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
| Headline | Source | Time |
|---|---|---|
Older | ||
BBiostock | ||
BBiostock | ||
BBiostock | ||
BBiostock | ||
 Gilead scoops up a preclinical cancer program The company, which invested heavily in oncology in recent years, has now put more than $400 million on the table to access a Sprint Bioscience drug targeting “TREX1.” | ||
BBiostock | ||
BBiostock | ||
DDagens Juridik | ||